[3]
The respondent, Novopharm, is the "second person" cited in section 2 and subsection 5(1) of the
NOC Regulations
. By letter dated December 20, 2002, Novopharm sent to Janssen-Ortho a Notice of Allegation ("NOA"), including a detailed statement of the legal and factual basis for its allegation, pursuant to paragraph 5(3)(c) of the
NOC Regulations
. It seeks a NOC to market 250 mg and 500 mg tablets of levofloxacin hemihydrate.